商標ウォッチ

公開日2025-10-16
公報種別公開国際商標公報
国際登録番号1870586
国際登録日2025-02-03
区分第1類(化学品),第5類(薬剤)
商品役務Antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways.,Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions 全 56 件を表示, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways.
基礎出願番号98840849
基礎出願日2024-11-06
基礎出願国US
出願人Constellation Pharmaceuticals, Inc.
OCRテキスト
OCRテキスト2
OCRについて

関連商標